Nanologica AB (SE:NICA)
:NICA
Want to see SE:NICA full AI Analyst Report?
NICA Stock Chart & Stats
kr0.74
kr0.03(1.43%)
At close: 4:00 PM EST
kr0.74
kr0.03(1.43%)
Day’s Range― - ―
52-Week Rangekr0.33 - kr2.25
Previous CloseN/A
Volume105.00
Average Volume (3M)111.94K
Market Cap
kr188.06M
Enterprise Valuekr133.48M
Total Cash (Recent Filing)kr39.25M
Total Debt (Recent Filing)kr119.07M
Price to Earnings (P/E)2.1
Beta1.39
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.27
Shares Outstanding328,769,840
10 Day Avg. Volume89,035
30 Day Avg. Volume111,941
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.04
Price to Sales (P/S)3.26
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr141.40M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained ~50% TTM revenue growth reflects accelerating commercial adoption of Nanologica's silica products in pharma applications. Durable top-line expansion supports scale economies, deeper customer relationships, and the potential to convert project work into recurring consumable sales over the next 2–6 months.
Proprietary Silica Technology PlatformA specialized porous silica platform for chromatographic media is a structural competitive advantage: high technical barriers, regulatory-qualified materials for drug purification, and switching costs for customers. This technological moat supports durable demand and pricing power in life-science workflows.
Positive Equity And Asset BaseA materially larger asset base and positive equity provide financial capacity to invest in scale-up, R&D and customer support. This capital buffer improves operational runway versus peers and enables the company to commercialize product demand despite near-term losses.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow (~-27M TTM) means the business relies on external financing to fund operations. Over months this raises dilution and refinancing risk, constrains reinvestment flexibility, and pressures capital allocation until cash generation turns positive.
Loss-Making At Operating LevelContinued negative gross and operating profits indicate the core business has not yet achieved margin sustainability. Even with revenue growth, operating losses require either structural margin expansion or durable non-operating support to achieve reliable, long-term profitability.
Rising LeverageA debt-to-equity near 1.22 while the company remains loss-making increases financial risk. Higher leverage reduces operational flexibility, elevates refinancing sensitivity, and can amplify downside in adverse scenarios until cash flow or profitability improves.
Nanologica AB News
NICA FAQ
What was Nanologica AB’s price range in the past 12 months?
Nanologica AB lowest stock price was kr0.33 and its highest was kr2.25 in the past 12 months.
What is Nanologica AB’s market cap?
Nanologica AB’s market cap is kr188.06M.
When is Nanologica AB’s upcoming earnings report date?
Nanologica AB’s upcoming earnings report date is Aug 27, 2026 which is in 66 days.
How were Nanologica AB’s earnings last quarter?
Nanologica AB released its earnings results on May 20, 2026. The company reported kr0.719 earnings per share for the quarter, beating the consensus estimate of N/A by kr0.719.
Is Nanologica AB overvalued?
According to Wall Street analysts Nanologica AB’s price is currently Overvalued.
Does Nanologica AB pay dividends?
Nanologica AB does not currently pay dividends.
What is Nanologica AB’s EPS estimate?
Nanologica AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanologica AB have?
Nanologica AB has 328,769,840 shares outstanding.
What happened to Nanologica AB’s price movement after its last earnings report?
Nanologica AB reported an EPS of kr0.719 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 32.383%.
Which hedge fund is a major shareholder of Nanologica AB?
Currently, no hedge funds are holding shares in SE:NICA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanologica AB
Founded in Södertälje, Sweden, in 2004, Nanologica AB (publ) is a nanotechnology company dedicated to creating nanoporous silica. This specialized material finds critical applications within the life science industry, particularly in drug development and chromatography separation. The firm's comprehensive product line features the NLAB Silica platform for advanced drug delivery, the NLAB Spiro inhalation platform targeting pulmonary administration, SVEA (U)HPLC analytical columns, and systems for preparative chromatography.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Biovica International AB Class B
―
NextCell Pharma AB
―
Spago Nanomedical AB
―